Healthcare provider profile · identity verified

Bret Hafen

Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · LAYTON, UT · NPI 1982060828

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Bret Hafen received $217,976.36 in general payments during 2025 across 493 reported records.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 49.8% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 14 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Abilify Maintena, Caplyta, Invega Sustenna, Invega Trinza, Vivitrol, Vraylar.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Vraylar by this doctor in 2024.

Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIVITROL as an associated drug or biological on 9533 records involving 5661 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vivitrol by this doctor in 2024.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Caplyta by this doctor in 2024.

Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Caplyta as an associated drug or biological on 11 records involving 9 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Caplyta by this doctor in 2024.

Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Invega Sustenna by this doctor in 2024.

Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA TRINZA as an associated drug or biological on 8191 records involving 2146 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Invega Trinza by this doctor in 2024.

Janssen Scientific Affairs, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 488 records involving 397 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Invega Sustenna by this doctor in 2024.

Janssen Scientific Affairs, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA TRINZA as an associated drug or biological on 23 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Invega Trinza by this doctor in 2024.

Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Abilify Maintena by this doctor in 2024.

Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Abilify Maintena by this doctor in 2024.

Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 87 records involving 83 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Abilify Maintena by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$217,976.36

493 reported records · 11 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	Unresolved — no canonical attribution shown	$108,581.84	49.8%	209	2025
Alkermes, Inc.	Unresolved — no canonical attribution shown	$36,850.14	16.9%	91	2025
ABBVIE INC.	Unresolved — no canonical attribution shown	$29,880.66	13.7%	95	2025
Janssen Pharmaceuticals, Inc	Unresolved — no canonical attribution shown	$29,082.86	13.3%	49	2025
E.R. Squibb & Sons, L.L.C.	Unresolved — no canonical attribution shown	$7,597.50	3.5%	27	2025
Otsuka America Pharmaceutical, Inc.	Unresolved — no canonical attribution shown	$5,483.60	2.5%	13	2025
Janssen Scientific Affairs, LLC	Unresolved — no canonical attribution shown	$218.56	0.1%	2	2025
Neurocrine BioSciences, Inc.	Unresolved — no canonical attribution shown	$145.18	0.1%	3	2025
Otsuka Pharmaceutical Development & Commercialization, Inc.	Unresolved — no canonical attribution shown	$70.61	0.0%	1	2025
Neuronetics, Inc.	Unresolved — no canonical attribution shown	$47.41	0.0%	2	2025
Lundbeck LLC	Unresolved — no canonical attribution shown	$18.00	0.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program	$162,389.00	102
Travel and Lodging	$33,999.80	146
Consulting Fee	$12,820.00	7
Food and Beverage	$8,762.11	237
Education	$5.45	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
CAPLYTA Normalized: caplyta	Drug	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	$108,581.84	209	2025
Source payment records 2025-01-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,540.00 · Open Payments source 2025-01-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $165.79 · Open Payments source 2025-01-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $156.80 · Open Payments source 2025-01-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $105.85 · Open Payments source 2025-01-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,760.00 · Open Payments source 2025-01-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $165.79 · Open Payments source 2025-01-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $49.00 · Open Payments source 2025-02-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $117.30 · Open Payments source 2025-02-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,760.00 · Open Payments source 2025-02-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $125.88 · Open Payments source 2025-02-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $136.52 · Open Payments source 2025-02-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $16.43 · Open Payments source 2025-02-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,420.00 · Open Payments source 2025-02-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $125.88 · Open Payments source 2025-02-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $136.52 · Open Payments source 2025-02-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.81 · Open Payments source 2025-02-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,540.00 · Open Payments source 2025-02-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $125.88 · Open Payments source 2025-02-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $136.52 · Open Payments source 2025-02-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $129.32 · Open Payments source 2025-02-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,760.00 · Open Payments source 2025-02-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $125.88 · Open Payments source 2025-02-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $136.52 · Open Payments source 2025-02-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $30.28 · Open Payments source 2025-02-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,760.00 · Open Payments source 2025-02-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $125.88 · Open Payments source 2025-02-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $136.52 · Open Payments source 2025-02-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $97.38 · Open Payments source 2025-02-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,100.00 · Open Payments source 2025-02-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $125.88 · Open Payments source 2025-02-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $136.52 · Open Payments source 2025-02-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $900.78 · Open Payments source 2025-02-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $52.76 · Open Payments source 2025-03-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $880.00 · Open Payments source 2025-03-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $73.00 · Open Payments source 2025-03-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $139.06 · Open Payments source 2025-03-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $79.01 · Open Payments source 2025-03-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,200.00 · Open Payments source 2025-03-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $423.98 · Open Payments source 2025-03-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $334.33 · Open Payments source 2025-03-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $99.81 · Open Payments source 2025-03-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,100.00 · Open Payments source 2025-03-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $423.98 · Open Payments source 2025-03-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $334.33 · Open Payments source 2025-03-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $188.62 · Open Payments source 2025-03-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $14.59 · Open Payments source 2025-03-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $114.97 · Open Payments source 2025-03-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,100.00 · Open Payments source 2025-03-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $62.57 · Open Payments source 2025-03-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $124.29 · Open Payments source 2025-03-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $29.68 · Open Payments source 2025-03-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,980.00 · Open Payments source 2025-03-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $62.57 · Open Payments source 2025-03-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $124.29 · Open Payments source 2025-03-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $474.60 · Open Payments source 2025-03-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $72.30 · Open Payments source 2025-03-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $23.90 · Open Payments source 2025-03-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $880.00 · Open Payments source 2025-03-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $62.57 · Open Payments source 2025-03-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $124.29 · Open Payments source 2025-04-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,540.00 · Open Payments source 2025-04-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $93.80 · Open Payments source 2025-04-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.81 · Open Payments source 2025-05-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $598.96 · Open Payments source 2025-05-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $500.19 · Open Payments source 2025-05-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $119.18 · Open Payments source 2025-05-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.48 · Open Payments source 2025-06-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,060.00 · Open Payments source 2025-06-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,020.00 · Open Payments source 2025-06-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $834.96 · Open Payments source 2025-06-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,056.60 · Open Payments source 2025-06-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $105.45 · Open Payments source 2025-06-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $126.78 · Open Payments source 2025-07-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $100.00 · Open Payments source 2025-07-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $55.19 · Open Payments source 2025-07-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $377.70 · Open Payments source 2025-07-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.39 · Open Payments source 2025-07-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $40.00 · Open Payments source 2025-07-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $21.47 · Open Payments source 2025-07-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,805.00 · Open Payments source 2025-07-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,060.00 · Open Payments source 2025-07-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,275.00 · Open Payments source 2025-07-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.15 · Open Payments source 2025-07-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $569.79 · Open Payments source 2025-07-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $846.97 · Open Payments source 2025-07-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $26.39 · Open Payments source 2025-07-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,785.00 · Open Payments source 2025-07-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,805.00 · Open Payments source 2025-07-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $37.50 · Open Payments source 2025-07-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $20.93 · Open Payments source 2025-07-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $27.31 · Open Payments source 2025-07-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $17.75 · Open Payments source 2025-07-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $10.92 · Open Payments source 2025-07-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $28.96 · Open Payments source 2025-07-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $250.68 · Open Payments source 2025-07-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $42.24 · Open Payments source 2025-07-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.69 · Open Payments source 2025-08-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $95.08 · Open Payments source 2025-08-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $33.32 · Open Payments source 2025-08-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $15.94 · Open Payments source 2025-08-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $372.33 · Open Payments source 2025-08-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $10.35 · Open Payments source 2025-08-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,785.00 · Open Payments source 2025-08-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.81 · Open Payments source 2025-08-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $93.80 · Open Payments source 2025-08-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,040.00 · Open Payments source 2025-08-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $96.60 · Open Payments source 2025-08-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.62 · Open Payments source 2025-09-08 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.33 · Open Payments source 2025-09-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,020.00 · Open Payments source 2025-09-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $36.40 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $137.50 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $138.53 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.29 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.29 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $275.45 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $44.30 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $457.97 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $46.64 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $52.94 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $59.43 · Open Payments source 2025-10-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $99.31 · Open Payments source 2025-10-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $16.72 · Open Payments source 2025-10-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $882.77 · Open Payments source 2025-10-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $393.24 · Open Payments source 2025-10-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $12.87 · Open Payments source 2025-10-21 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $28.89 · Open Payments source 2025-10-21 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $108.23 · Open Payments source 2025-10-21 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $526.79 · Open Payments source 2025-10-21 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $256.25 · Open Payments source 2025-10-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $262.57 · Open Payments source 2025-10-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $20.43 · Open Payments source 2025-10-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $129.05 · Open Payments source 2025-10-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $34.21 · Open Payments source 2025-10-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $14.22 · Open Payments source 2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,295.00 · Open Payments source 2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,275.00 · Open Payments source 2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2.00 · Open Payments source 2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $72.29 · Open Payments source 2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $6.65 · Open Payments source 2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4.95 · Open Payments source 2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4.32 · Open Payments source 2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $21.13 · Open Payments source 2025-10-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $556.96 · Open Payments source 2025-10-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $523.02 · Open Payments source 2025-10-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $116.99 · Open Payments source 2025-10-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $16.37 · Open Payments source 2025-11-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4.77 · Open Payments source 2025-11-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,805.00 · Open Payments source 2025-11-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $47.39 · Open Payments source 2025-11-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $405.50 · Open Payments source 2025-11-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $31.96 · Open Payments source 2025-11-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $20.04 · Open Payments source 2025-11-07 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $27.03 · Open Payments source 2025-11-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $15.30 · Open Payments source 2025-11-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $135.68 · Open Payments source 2025-11-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,040.00 · Open Payments source 2025-11-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,040.00 · Open Payments source 2025-11-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,040.00 · Open Payments source 2025-11-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,785.00 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $72.80 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $11.20 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $7.00 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $20.86 · Open Payments source 2025-11-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $16.64 · Open Payments source 2025-11-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,040.00 · Open Payments source 2025-11-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $6.87 · Open Payments source 2025-11-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4.95 · Open Payments source 2025-11-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3.00 · Open Payments source 2025-11-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $331.00 · Open Payments source 2025-11-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $32.44 · Open Payments source 2025-11-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,785.00 · Open Payments source 2025-11-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,020.00 · Open Payments source 2025-11-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,020.00 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,275.00 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.55 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $223.05 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4.95 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $59.33 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $545.49 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,805.00 · Open Payments source 2025-12-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $106.48 · Open Payments source 2025-12-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $974.85 · Open Payments source 2025-12-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $402.11 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $23.23 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $100.83 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $7.48 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2.02 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $5.00 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.77 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $247.53 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $71.26 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $15.28 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $59.34 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $278.60 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $34.96 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $444.95 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,785.00 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,020.00 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,785.00 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,785.00 · Open Payments source 2025-12-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $7.05 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,020.00 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,275.00 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,550.00 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,295.00 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,805.00 · Open Payments source 2025-12-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4.20 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.28 · Open Payments source
LYBALVI Normalized: lybalvi	Drug	Alkermes, Inc.	$34,303.00	84	2025
Source payment records 2025-01-09 · Alkermes, Inc. · $17.00 · Open Payments source 2025-01-23 · Alkermes, Inc. · $124.70 · Open Payments source 2025-03-04 · Alkermes, Inc. · $12.33 · Open Payments source 2025-03-25 · Alkermes, Inc. · $15.60 · Open Payments source 2025-04-04 · Alkermes, Inc. · $23.27 · Open Payments source 2025-04-04 · Alkermes, Inc. · $125.00 · Open Payments source 2025-04-04 · Alkermes, Inc. · $24.95 · Open Payments source 2025-04-05 · Alkermes, Inc. · $601.96 · Open Payments source 2025-04-05 · Alkermes, Inc. · $238.26 · Open Payments source 2025-04-05 · Alkermes, Inc. · $2.88 · Open Payments source 2025-04-05 · Alkermes, Inc. · $23.27 · Open Payments source 2025-04-05 · Alkermes, Inc. · $60.00 · Open Payments source 2025-04-05 · Alkermes, Inc. · $48.66 · Open Payments source 2025-04-05 · Alkermes, Inc. · $75.00 · Open Payments source 2025-04-05 · Alkermes, Inc. · $17.85 · Open Payments source 2025-04-05 · Alkermes, Inc. · $23.00 · Open Payments source 2025-04-16 · Alkermes, Inc. · $13.32 · Open Payments source 2025-04-24 · Alkermes, Inc. · $3,820.00 · Open Payments source 2025-04-30 · Alkermes, Inc. · $29.03 · Open Payments source 2025-05-07 · Alkermes, Inc. · $104.97 · Open Payments source 2025-05-07 · Alkermes, Inc. · $483.84 · Open Payments source 2025-05-08 · Alkermes, Inc. · $16.08 · Open Payments source 2025-05-09 · Alkermes, Inc. · $14.49 · Open Payments source 2025-05-12 · Alkermes, Inc. · $21.67 · Open Payments source 2025-05-16 · Alkermes, Inc. · $16.80 · Open Payments source 2025-05-20 · Alkermes, Inc. · $1,350.00 · Open Payments source 2025-05-20 · Alkermes, Inc. · $1,460.00 · Open Payments source 2025-05-20 · Alkermes, Inc. · $1,460.00 · Open Payments source 2025-05-20 · Alkermes, Inc. · $1,350.00 · Open Payments source 2025-05-20 · Alkermes, Inc. · $1,800.00 · Open Payments source 2025-05-20 · Alkermes, Inc. · $1,350.00 · Open Payments source 2025-05-22 · Alkermes, Inc. · $26.50 · Open Payments source 2025-05-22 · Alkermes, Inc. · $45.39 · Open Payments source 2025-05-22 · Alkermes, Inc. · $4.95 · Open Payments source 2025-05-22 · Alkermes, Inc. · $9.00 · Open Payments source 2025-05-22 · Alkermes, Inc. · $274.40 · Open Payments source 2025-05-22 · Alkermes, Inc. · $28.91 · Open Payments source 2025-05-22 · Alkermes, Inc. · $197.40 · Open Payments source 2025-05-22 · Alkermes, Inc. · $100.80 · Open Payments source 2025-05-27 · Alkermes, Inc. · $15.30 · Open Payments source 2025-06-09 · Alkermes, Inc. · $16.44 · Open Payments source 2025-06-12 · Alkermes, Inc. · $60.97 · Open Payments source 2025-07-02 · Alkermes, Inc. · $95.20 · Open Payments source 2025-07-02 · Alkermes, Inc. · $1,800.00 · Open Payments source 2025-07-02 · Alkermes, Inc. · $11.33 · Open Payments source 2025-07-23 · Alkermes, Inc. · $16.75 · Open Payments source 2025-08-13 · Alkermes, Inc. · $560.00 · Open Payments source 2025-08-14 · Alkermes, Inc. · $656.59 · Open Payments source 2025-08-14 · Alkermes, Inc. · $126.09 · Open Payments source 2025-08-28 · Alkermes, Inc. · $31.53 · Open Payments source 2025-09-02 · Alkermes, Inc. · $26.35 · Open Payments source 2025-09-04 · Alkermes, Inc. · $15.70 · Open Payments source 2025-09-11 · Alkermes, Inc. · $1,350.00 · Open Payments source 2025-09-16 · Alkermes, Inc. · $1,350.00 · Open Payments source 2025-09-18 · Alkermes, Inc. · $547.82 · Open Payments source 2025-09-18 · Alkermes, Inc. · $23.47 · Open Payments source 2025-09-18 · Alkermes, Inc. · $55.10 · Open Payments source 2025-09-18 · Alkermes, Inc. · $279.20 · Open Payments source 2025-09-22 · Alkermes, Inc. · $20.63 · Open Payments source 2025-09-24 · Alkermes, Inc. · $684.51 · Open Payments source 2025-09-24 · Alkermes, Inc. · $32.27 · Open Payments source 2025-09-24 · Alkermes, Inc. · $81.56 · Open Payments source 2025-09-25 · Alkermes, Inc. · $95.00 · Open Payments source 2025-09-25 · Alkermes, Inc. · $31.62 · Open Payments source 2025-09-26 · Alkermes, Inc. · $2,250.00 · Open Payments source 2025-10-07 · Alkermes, Inc. · $89.60 · Open Payments source 2025-10-07 · Alkermes, Inc. · $135.10 · Open Payments source 2025-10-07 · Alkermes, Inc. · $4.20 · Open Payments source 2025-10-07 · Alkermes, Inc. · $20.12 · Open Payments source 2025-10-16 · Alkermes, Inc. · $1,235.00 · Open Payments source 2025-10-16 · Alkermes, Inc. · $1,235.00 · Open Payments source 2025-10-16 · Alkermes, Inc. · $1,350.00 · Open Payments source 2025-10-16 · Alkermes, Inc. · $1,460.00 · Open Payments source 2025-10-16 · Alkermes, Inc. · $174.30 · Open Payments source 2025-10-16 · Alkermes, Inc. · $1,460.00 · Open Payments source 2025-10-16 · Alkermes, Inc. · $39.20 · Open Payments source 2025-10-23 · Alkermes, Inc. · $18.54 · Open Payments source 2025-11-11 · Alkermes, Inc. · $20.86 · Open Payments source 2025-11-12 · Alkermes, Inc. · $13.72 · Open Payments source 2025-11-25 · Alkermes, Inc. · $15.07 · Open Payments source 2025-11-25 · Alkermes, Inc. · $1,350.00 · Open Payments source 2025-12-10 · Alkermes, Inc. · $6.30 · Open Payments source 2025-12-16 · Alkermes, Inc. · $14.80 · Open Payments source 2025-12-17 · Alkermes, Inc. · $16.48 · Open Payments source
INVEGA SUSTENNA Normalized: invega sustenna	Drug	Janssen Pharmaceuticals, Inc, Janssen Scientific Affairs, LLC	$28,888.58	44	2025
Source payment records 2025-04-29 · Janssen Scientific Affairs, LLC · $82.57 · Open Payments source 2025-04-30 · Janssen Pharmaceuticals, Inc · $1,320.00 · Open Payments source 2025-07-09 · Janssen Pharmaceuticals, Inc · $440.00 · Open Payments source 2025-09-03 · Janssen Pharmaceuticals, Inc · $1,057.72 · Open Payments source 2025-09-16 · Janssen Pharmaceuticals, Inc · $5.50 · Open Payments source 2025-09-18 · Janssen Pharmaceuticals, Inc · $579.65 · Open Payments source 2025-09-18 · Janssen Pharmaceuticals, Inc · $20.22 · Open Payments source 2025-09-18 · Janssen Pharmaceuticals, Inc · $123.60 · Open Payments source 2025-09-18 · Janssen Pharmaceuticals, Inc · $135.29 · Open Payments source 2025-09-19 · Janssen Pharmaceuticals, Inc · $369.79 · Open Payments source 2025-09-24 · Janssen Pharmaceuticals, Inc · $3,080.00 · Open Payments source 2025-09-24 · Janssen Pharmaceuticals, Inc · $1,540.00 · Open Payments source 2025-09-24 · Janssen Pharmaceuticals, Inc · $3,080.00 · Open Payments source 2025-09-30 · Janssen Pharmaceuticals, Inc · $37.94 · Open Payments source 2025-10-02 · Janssen Pharmaceuticals, Inc · $572.43 · Open Payments source 2025-10-06 · Janssen Pharmaceuticals, Inc · $45.23 · Open Payments source 2025-10-06 · Janssen Pharmaceuticals, Inc · $23.32 · Open Payments source 2025-10-06 · Janssen Pharmaceuticals, Inc · $19.27 · Open Payments source 2025-10-06 · Janssen Pharmaceuticals, Inc · $64.82 · Open Payments source 2025-10-10 · Janssen Pharmaceuticals, Inc · $49.50 · Open Payments source 2025-10-15 · Janssen Pharmaceuticals, Inc · $46.27 · Open Payments source 2025-10-15 · Janssen Pharmaceuticals, Inc · $98.65 · Open Payments source 2025-10-16 · Janssen Pharmaceuticals, Inc · $596.11 · Open Payments source 2025-10-16 · Janssen Pharmaceuticals, Inc · $42.43 · Open Payments source 2025-10-16 · Janssen Pharmaceuticals, Inc · $100.00 · Open Payments source 2025-10-17 · Janssen Pharmaceuticals, Inc · $3,080.00 · Open Payments source 2025-10-17 · Janssen Pharmaceuticals, Inc · $1,540.00 · Open Payments source 2025-10-21 · Janssen Pharmaceuticals, Inc · $1,540.00 · Open Payments source 2025-10-21 · Janssen Pharmaceuticals, Inc · $3,080.00 · Open Payments source 2025-10-24 · Janssen Pharmaceuticals, Inc · $713.55 · Open Payments source 2025-10-28 · Janssen Pharmaceuticals, Inc · $228.10 · Open Payments source 2025-10-29 · Janssen Pharmaceuticals, Inc · $228.10 · Open Payments source 2025-11-13 · Janssen Pharmaceuticals, Inc · $125.00 · Open Payments source 2025-11-14 · Janssen Pharmaceuticals, Inc · $35.00 · Open Payments source 2025-11-14 · Janssen Pharmaceuticals, Inc · $4.95 · Open Payments source 2025-11-14 · Janssen Pharmaceuticals, Inc · $237.49 · Open Payments source 2025-11-14 · Janssen Pharmaceuticals, Inc · $75.45 · Open Payments source 2025-11-20 · Janssen Pharmaceuticals, Inc · $118.99 · Open Payments source 2025-11-21 · Janssen Pharmaceuticals, Inc · $441.80 · Open Payments source 2025-11-25 · Janssen Pharmaceuticals, Inc · $3,080.00 · Open Payments source 2025-12-18 · Janssen Pharmaceuticals, Inc · $660.00 · Open Payments source 2025-12-22 · Janssen Pharmaceuticals, Inc · $37.54 · Open Payments source 2025-12-22 · Janssen Pharmaceuticals, Inc · $34.91 · Open Payments source 2025-12-22 · Janssen Pharmaceuticals, Inc · $97.39 · Open Payments source
VRAYLAR Normalized: vraylar	Drug	ABBVIE INC.	$28,731.89	93	2025
Source payment records 2025-01-07 · ABBVIE INC. · $15.23 · Open Payments source 2025-01-22 · ABBVIE INC. · $79.80 · Open Payments source 2025-01-22 · ABBVIE INC. · $16.26 · Open Payments source 2025-01-22 · ABBVIE INC. · $15.56 · Open Payments source 2025-01-24 · ABBVIE INC. · $15.01 · Open Payments source 2025-01-30 · ABBVIE INC. · $20.45 · Open Payments source 2025-02-06 · ABBVIE INC. · $12.50 · Open Payments source 2025-02-11 · ABBVIE INC. · $1,125.00 · Open Payments source 2025-02-18 · ABBVIE INC. · $25.07 · Open Payments source 2025-02-18 · ABBVIE INC. · $82.60 · Open Payments source 2025-02-19 · ABBVIE INC. · $12.56 · Open Payments source 2025-02-19 · ABBVIE INC. · $0.14 · Open Payments source 2025-02-19 · ABBVIE INC. · $21.00 · Open Payments source 2025-02-20 · ABBVIE INC. · $22.53 · Open Payments source 2025-02-20 · ABBVIE INC. · $93.10 · Open Payments source 2025-02-25 · ABBVIE INC. · $12.36 · Open Payments source 2025-02-25 · ABBVIE INC. · $6.52 · Open Payments source 2025-02-27 · ABBVIE INC. · $1,125.00 · Open Payments source 2025-03-03 · ABBVIE INC. · $20.47 · Open Payments source 2025-03-03 · ABBVIE INC. · $40.60 · Open Payments source 2025-03-04 · ABBVIE INC. · $1,125.00 · Open Payments source 2025-03-06 · ABBVIE INC. · $12.59 · Open Payments source 2025-03-06 · ABBVIE INC. · $7.71 · Open Payments source 2025-03-07 · ABBVIE INC. · $25.27 · Open Payments source 2025-03-07 · ABBVIE INC. · $77.00 · Open Payments source 2025-03-10 · ABBVIE INC. · $22.10 · Open Payments source 2025-03-10 · ABBVIE INC. · $93.80 · Open Payments source 2025-03-11 · ABBVIE INC. · $1,575.00 · Open Payments source 2025-03-11 · ABBVIE INC. · $1,125.00 · Open Payments source 2025-03-18 · ABBVIE INC. · $1,125.00 · Open Payments source 2025-03-18 · ABBVIE INC. · $10.62 · Open Payments source 2025-03-18 · ABBVIE INC. · $1,125.00 · Open Payments source 2025-03-25 · ABBVIE INC. · $1,125.00 · Open Payments source 2025-03-27 · ABBVIE INC. · $16.40 · Open Payments source 2025-04-07 · ABBVIE INC. · $1,575.00 · Open Payments source 2025-04-09 · ABBVIE INC. · $17.29 · Open Payments source 2025-04-14 · ABBVIE INC. · $19.24 · Open Payments source 2025-04-14 · ABBVIE INC. · $119.00 · Open Payments source 2025-04-23 · ABBVIE INC. · $8.45 · Open Payments source 2025-05-02 · ABBVIE INC. · $1,575.00 · Open Payments source 2025-05-06 · ABBVIE INC. · $13.04 · Open Payments source 2025-05-20 · ABBVIE INC. · $13.27 · Open Payments source 2025-05-20 · ABBVIE INC. · $2.83 · Open Payments source 2025-06-03 · ABBVIE INC. · $15.63 · Open Payments source 2025-06-03 · ABBVIE INC. · $562.50 · Open Payments source 2025-06-11 · ABBVIE INC. · $12.54 · Open Payments source 2025-06-11 · ABBVIE INC. · $22.73 · Open Payments source 2025-06-11 · ABBVIE INC. · $89.60 · Open Payments source 2025-06-12 · ABBVIE INC. · $26.26 · Open Payments source 2025-06-13 · ABBVIE INC. · $20.47 · Open Payments source 2025-06-13 · ABBVIE INC. · $50.40 · Open Payments source 2025-06-18 · ABBVIE INC. · $9.79 · Open Payments source 2025-07-02 · ABBVIE INC. · $1,575.00 · Open Payments source 2025-07-02 · ABBVIE INC. · $12.05 · Open Payments source 2025-07-02 · ABBVIE INC. · $1,575.00 · Open Payments source 2025-07-02 · ABBVIE INC. · $1,125.00 · Open Payments source 2025-07-14 · ABBVIE INC. · $18.91 · Open Payments source 2025-07-15 · ABBVIE INC. · $4.42 · Open Payments source 2025-07-16 · ABBVIE INC. · $8.75 · Open Payments source 2025-07-23 · ABBVIE INC. · $648.62 · Open Payments source 2025-07-24 · ABBVIE INC. · $118.92 · Open Payments source 2025-07-24 · ABBVIE INC. · $40.00 · Open Payments source 2025-07-24 · ABBVIE INC. · $16.09 · Open Payments source 2025-07-24 · ABBVIE INC. · $462.70 · Open Payments source 2025-07-24 · ABBVIE INC. · $6.00 · Open Payments source 2025-07-28 · ABBVIE INC. · $10.01 · Open Payments source 2025-08-04 · ABBVIE INC. · $25.80 · Open Payments source 2025-08-04 · ABBVIE INC. · $26.56 · Open Payments source 2025-08-04 · ABBVIE INC. · $91.00 · Open Payments source 2025-08-06 · ABBVIE INC. · $5.87 · Open Payments source 2025-08-08 · ABBVIE INC. · $1,575.00 · Open Payments source 2025-08-08 · ABBVIE INC. · $1,125.00 · Open Payments source 2025-08-08 · ABBVIE INC. · $1,125.00 · Open Payments source 2025-08-13 · ABBVIE INC. · $10.36 · Open Payments source 2025-08-14 · ABBVIE INC. · $120.00 · Open Payments source 2025-08-14 · ABBVIE INC. · $1,575.00 · Open Payments source 2025-08-19 · ABBVIE INC. · $16.83 · Open Payments source 2025-08-21 · ABBVIE INC. · $1,125.00 · Open Payments source 2025-08-21 · ABBVIE INC. · $23.99 · Open Payments source 2025-08-28 · ABBVIE INC. · $14.88 · Open Payments source 2025-09-17 · ABBVIE INC. · $13.99 · Open Payments source 2025-09-25 · ABBVIE INC. · $562.50 · Open Payments source 2025-10-02 · ABBVIE INC. · $8.22 · Open Payments source 2025-10-14 · ABBVIE INC. · $14.25 · Open Payments source 2025-10-29 · ABBVIE INC. · $5.02 · Open Payments source 2025-11-05 · ABBVIE INC. · $7.58 · Open Payments source 2025-11-12 · ABBVIE INC. · $7.61 · Open Payments source 2025-11-20 · ABBVIE INC. · $7.36 · Open Payments source 2025-11-25 · ABBVIE INC. · $12.72 · Open Payments source 2025-12-03 · ABBVIE INC. · $11.61 · Open Payments source 2025-12-11 · ABBVIE INC. · $22.58 · Open Payments source 2025-12-11 · ABBVIE INC. · $71.40 · Open Payments source 2025-12-18 · ABBVIE INC. · $1,125.00 · Open Payments source
INVEGA TRINZA Normalized: invega trinza	Drug	Janssen Pharmaceuticals, Inc	$27,957.62	33	2025
Source payment records 2025-04-30 · Janssen Pharmaceuticals, Inc · $1,320.00 · Open Payments source 2025-07-09 · Janssen Pharmaceuticals, Inc · $440.00 · Open Payments source 2025-09-03 · Janssen Pharmaceuticals, Inc · $1,057.72 · Open Payments source 2025-09-16 · Janssen Pharmaceuticals, Inc · $5.50 · Open Payments source 2025-09-18 · Janssen Pharmaceuticals, Inc · $579.65 · Open Payments source 2025-09-19 · Janssen Pharmaceuticals, Inc · $369.79 · Open Payments source 2025-09-24 · Janssen Pharmaceuticals, Inc · $3,080.00 · Open Payments source 2025-09-24 · Janssen Pharmaceuticals, Inc · $1,540.00 · Open Payments source 2025-09-24 · Janssen Pharmaceuticals, Inc · $3,080.00 · Open Payments source 2025-10-02 · Janssen Pharmaceuticals, Inc · $572.43 · Open Payments source 2025-10-06 · Janssen Pharmaceuticals, Inc · $45.23 · Open Payments source 2025-10-06 · Janssen Pharmaceuticals, Inc · $23.32 · Open Payments source 2025-10-06 · Janssen Pharmaceuticals, Inc · $19.27 · Open Payments source 2025-10-06 · Janssen Pharmaceuticals, Inc · $64.82 · Open Payments source 2025-10-10 · Janssen Pharmaceuticals, Inc · $49.50 · Open Payments source 2025-10-16 · Janssen Pharmaceuticals, Inc · $596.11 · Open Payments source 2025-10-17 · Janssen Pharmaceuticals, Inc · $3,080.00 · Open Payments source 2025-10-17 · Janssen Pharmaceuticals, Inc · $1,540.00 · Open Payments source 2025-10-21 · Janssen Pharmaceuticals, Inc · $1,540.00 · Open Payments source 2025-10-21 · Janssen Pharmaceuticals, Inc · $3,080.00 · Open Payments source 2025-10-24 · Janssen Pharmaceuticals, Inc · $713.55 · Open Payments source 2025-10-28 · Janssen Pharmaceuticals, Inc · $228.10 · Open Payments source 2025-10-29 · Janssen Pharmaceuticals, Inc · $228.10 · Open Payments source 2025-11-14 · Janssen Pharmaceuticals, Inc · $35.00 · Open Payments source 2025-11-14 · Janssen Pharmaceuticals, Inc · $4.95 · Open Payments source 2025-11-14 · Janssen Pharmaceuticals, Inc · $237.49 · Open Payments source 2025-11-14 · Janssen Pharmaceuticals, Inc · $75.45 · Open Payments source 2025-11-21 · Janssen Pharmaceuticals, Inc · $441.80 · Open Payments source 2025-11-25 · Janssen Pharmaceuticals, Inc · $3,080.00 · Open Payments source 2025-12-18 · Janssen Pharmaceuticals, Inc · $660.00 · Open Payments source 2025-12-22 · Janssen Pharmaceuticals, Inc · $37.54 · Open Payments source 2025-12-22 · Janssen Pharmaceuticals, Inc · $34.91 · Open Payments source 2025-12-22 · Janssen Pharmaceuticals, Inc · $97.39 · Open Payments source
ABILIFY ASIMTUFII Normalized: abilify asimtufii	Drug	Otsuka America Pharmaceutical, Inc.	$3,136.30	10	2025
Source payment records 2025-05-01 · Otsuka America Pharmaceutical, Inc. · $1,160.00 · Open Payments source 2025-05-01 · Otsuka America Pharmaceutical, Inc. · $1,160.00 · Open Payments source 2025-05-07 · Otsuka America Pharmaceutical, Inc. · $72.80 · Open Payments source 2025-05-07 · Otsuka America Pharmaceutical, Inc. · $40.60 · Open Payments source 2025-05-09 · Otsuka America Pharmaceutical, Inc. · $161.00 · Open Payments source 2025-07-02 · Otsuka America Pharmaceutical, Inc. · $483.00 · Open Payments source 2025-10-06 · Otsuka America Pharmaceutical, Inc. · $15.67 · Open Payments source 2025-10-29 · Otsuka America Pharmaceutical, Inc. · $12.45 · Open Payments source 2025-11-11 · Otsuka America Pharmaceutical, Inc. · $18.33 · Open Payments source 2025-12-09 · Otsuka America Pharmaceutical, Inc. · $12.45 · Open Payments source
ABILIFY MAINTENA Normalized: abilify maintena	Drug	Otsuka America Pharmaceutical, Inc.	$3,077.40	6	2025
Source payment records 2025-05-01 · Otsuka America Pharmaceutical, Inc. · $1,160.00 · Open Payments source 2025-05-01 · Otsuka America Pharmaceutical, Inc. · $1,160.00 · Open Payments source 2025-05-07 · Otsuka America Pharmaceutical, Inc. · $72.80 · Open Payments source 2025-05-07 · Otsuka America Pharmaceutical, Inc. · $40.60 · Open Payments source 2025-05-09 · Otsuka America Pharmaceutical, Inc. · $161.00 · Open Payments source 2025-07-02 · Otsuka America Pharmaceutical, Inc. · $483.00 · Open Payments source
VIVITROL Normalized: vivitrol	Drug	Alkermes, Inc.	$2,547.14	7	2025
Source payment records 2025-01-29 · Alkermes, Inc. · $4.48 · Open Payments source 2025-04-16 · Alkermes, Inc. · $560.00 · Open Payments source 2025-08-07 · Alkermes, Inc. · $14.82 · Open Payments source 2025-11-18 · Alkermes, Inc. · $122.64 · Open Payments source 2025-12-10 · Alkermes, Inc. · $32.20 · Open Payments source 2025-12-10 · Alkermes, Inc. · $13.00 · Open Payments source 2025-12-17 · Alkermes, Inc. · $1,800.00 · Open Payments source
REXULTI Normalized: rexulti	Drug	Lundbeck LLC, Otsuka America Pharmaceutical, Inc.	$2,365.30	4	2025
Source payment records 2025-01-04 · Otsuka America Pharmaceutical, Inc. · $1,160.00 · Open Payments source 2025-02-05 · Otsuka America Pharmaceutical, Inc. · $27.30 · Open Payments source 2025-02-12 · Otsuka America Pharmaceutical, Inc. · $1,160.00 · Open Payments source 2025-04-22 · Lundbeck LLC · $18.00 · Open Payments source
COBENFY Normalized: cobenfy	Drug	E.R. Squibb & Sons, L.L.C.	$1,757.50	24	2025
Source payment records 2025-04-03 · E.R. Squibb & Sons, L.L.C. · $131.16 · Open Payments source 2025-04-16 · E.R. Squibb & Sons, L.L.C. · $4.85 · Open Payments source 2025-04-16 · E.R. Squibb & Sons, L.L.C. · $6.98 · Open Payments source 2025-07-08 · E.R. Squibb & Sons, L.L.C. · $3.14 · Open Payments source 2025-08-11 · E.R. Squibb & Sons, L.L.C. · $7.57 · Open Payments source 2025-08-11 · E.R. Squibb & Sons, L.L.C. · $3.74 · Open Payments source 2025-08-20 · E.R. Squibb & Sons, L.L.C. · $6.71 · Open Payments source 2025-09-11 · E.R. Squibb & Sons, L.L.C. · $1.59 · Open Payments source 2025-09-11 · E.R. Squibb & Sons, L.L.C. · $6.69 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $49.99 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $770.02 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $64.99 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $326.09 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $29.99 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $29.99 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $134.99 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $51.73 · Open Payments source 2025-10-21 · E.R. Squibb & Sons, L.L.C. · $4.06 · Open Payments source 2025-11-04 · E.R. Squibb & Sons, L.L.C. · $4.80 · Open Payments source 2025-11-10 · E.R. Squibb & Sons, L.L.C. · $65.90 · Open Payments source 2025-11-10 · E.R. Squibb & Sons, L.L.C. · $22.18 · Open Payments source 2025-12-17 · E.R. Squibb & Sons, L.L.C. · $5.89 · Open Payments source 2025-12-17 · E.R. Squibb & Sons, L.L.C. · $18.73 · Open Payments source 2025-12-17 · E.R. Squibb & Sons, L.L.C. · $5.72 · Open Payments source
SPRAVATO Normalized: spravato	Drug	Janssen Pharmaceuticals, Inc, Janssen Scientific Affairs, LLC	$279.79	5	2025
Source payment records 2025-02-21 · Janssen Pharmaceuticals, Inc · $8.21 · Open Payments source 2025-03-06 · Janssen Pharmaceuticals, Inc · $121.52 · Open Payments source 2025-03-18 · Janssen Pharmaceuticals, Inc · $7.36 · Open Payments source 2025-04-10 · Janssen Scientific Affairs, LLC · $135.99 · Open Payments source 2025-05-20 · Janssen Pharmaceuticals, Inc · $6.71 · Open Payments source
INGREZZA Normalized: ingrezza	Drug	Neurocrine BioSciences, Inc.	$145.18	3	2025
Source payment records 2025-04-29 · Neurocrine BioSciences, Inc. · $14.34 · Open Payments source 2025-07-31 · Neurocrine BioSciences, Inc. · $112.76 · Open Payments source 2025-09-03 · Neurocrine BioSciences, Inc. · $18.08 · Open Payments source
ARISTADA Normalized: aristada	Drug	Alkermes, Inc.	$124.70	1	2025
Source payment records 2025-01-23 · Alkermes, Inc. · $124.70 · Open Payments source
NEUROSTAR TMS THERAPY SYSTEM Normalized: neurostar tms therapy system	Device	Neuronetics, Inc.	$47.41	2	2025
Source payment records 2025-02-07 · Neuronetics, Inc. · $28.54 · Open Payments source 2025-06-27 · Neuronetics, Inc. · $18.87 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
ABILIFY MAINTENA abilify maintena	2025	Abilify Maintena	2024	30 Beneficiary count suppressed	exact normalized	Medicare Part D
CAPLYTA caplyta	2025	Caplyta	2024	15 Beneficiary count suppressed	exact normalized	Medicare Part D
INVEGA SUSTENNA invega sustenna	2025	Invega Sustenna	2024	79 Beneficiary count suppressed	exact normalized	Medicare Part D
INVEGA TRINZA invega trinza	2025	Invega Trinza	2024	21 Beneficiary count suppressed	exact normalized	Medicare Part D
VIVITROL vivitrol	2025	Vivitrol	2024	14 Beneficiary count suppressed	exact normalized	Medicare Part D
VRAYLAR vraylar	2025	Vraylar	2024	21 Beneficiary count suppressed	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	VRAYLAR open payments reported associated product	CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550	Vraylar · 2024 Exact normalized brand match · 1 Part D row	21	suppressed by CMS
Alkermes, Inc. Exact reporting entity; no affiliate inference	2025	VIVITROL open payments reported associated product	CMS Open Payments — General Payments 9533 supporting records · 5661 recipient NPIs · example record 1222428584	Vivitrol · 2024 Exact normalized brand match · 1 Part D row	14	suppressed by CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference	2025	CAPLYTA open payments reported associated product	CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071	Caplyta · 2024 Exact normalized brand match · 1 Part D row	15	suppressed by CMS
Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference	2025	Caplyta open payments reported associated product	CMS Open Payments — General Payments 11 supporting records · 9 recipient NPIs · example record 1174547314	Caplyta · 2024 Exact normalized brand match · 1 Part D row	15	suppressed by CMS
Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference	2025	INVEGA SUSTENNA open payments reported associated product	CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262	Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row	79	suppressed by CMS
Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference	2025	INVEGA TRINZA open payments reported associated product	CMS Open Payments — General Payments 8191 supporting records · 2146 recipient NPIs · example record 1174223262	Invega Trinza · 2024 Exact normalized brand match · 1 Part D row	21	suppressed by CMS
Janssen Scientific Affairs, LLC Exact reporting entity; no affiliate inference	2025	INVEGA SUSTENNA open payments reported associated product	CMS Open Payments — General Payments 488 supporting records · 397 recipient NPIs · example record 1174147651	Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row	79	suppressed by CMS
Janssen Scientific Affairs, LLC Exact reporting entity; no affiliate inference	2025	INVEGA TRINZA open payments reported associated product	CMS Open Payments — General Payments 23 supporting records · 23 recipient NPIs · example record 1174152815	Invega Trinza · 2024 Exact normalized brand match · 1 Part D row	21	suppressed by CMS
Lundbeck LLC Exact reporting entity; no affiliate inference	2025	ABILIFY MAINTENA open payments reported associated product	CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994	Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row	30	suppressed by CMS
Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference	2025	ABILIFY MAINTENA open payments reported associated product	CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721	Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row	30	suppressed by CMS
Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference	2025	ABILIFY MAINTENA open payments reported associated product	CMS Open Payments — General Payments 87 supporting records · 83 recipient NPIs · example record 1225319985	Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row	30	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Lamotrigine	Lamotrigine	130	27
Quetiapine Fumarate	Quetiapine Fumarate	96	16
Clozapine	Clozapine	88	suppressed
Invega Sustenna	Paliperidone Palmitate	79	suppressed
Propranolol Hcl	Propranolol Hcl	57	suppressed
Bupropion Xl	Bupropion Hcl	52	suppressed
Duloxetine Hcl	Duloxetine Hcl	52	13
Fluoxetine Hcl	Fluoxetine Hcl	51	suppressed
Trazodone Hcl	Trazodone Hcl	51	18
Mirtazapine	Mirtazapine	40	suppressed
Aripiprazole	Aripiprazole	37	suppressed
Lurasidone Hcl	Lurasidone Hcl	35	suppressed
Clonazepam	Clonazepam	34	suppressed
Olanzapine	Olanzapine	34	suppressed
Lithium Carbonate	Lithium Carbonate	32	suppressed
Lithium Carbonate Er	Lithium Carbonate	31	suppressed
Abilify Maintena	Aripiprazole	30	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	30	suppressed
Gabapentin	Gabapentin	29	suppressed
Olanzapine Odt	Olanzapine	29	suppressed
Sertraline Hcl	Sertraline Hcl	29	suppressed
Lisdexamfetamine Dimesylate	Lisdexamfetamine Dimesylate	28	suppressed
Divalproex Sodium	Divalproex Sodium	27	suppressed
Divalproex Sodium Er	Divalproex Sodium	26	suppressed
Benztropine Mesylate	Benztropine Mesylate	25	suppressed
Ramelteon	Ramelteon	25	suppressed
Topiramate	Topiramate	22	suppressed
Buspirone Hcl	Buspirone Hcl	21	suppressed
Citalopram Hbr	Citalopram Hydrobromide	21	suppressed
Clonidine Hcl	Clonidine Hcl	21	suppressed
Invega Trinza	Paliperidone Palmitate	21	suppressed
Vraylar	Cariprazine Hcl	21	suppressed
Prazosin Hcl	Prazosin Hcl	20	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	18	suppressed
Ziprasidone Hcl	Ziprasidone Hcl	18	suppressed
Caplyta	Lumateperone Tosylate	15	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	15	suppressed
Oxcarbazepine	Oxcarbazepine	15	suppressed
Risperidone	Risperidone	15	suppressed
Belsomra	Suvorexant	14	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	14	suppressed
Vivitrol	Naltrexone Microspheres	14	suppressed
Amantadine	Amantadine Hcl	13	suppressed
Haloperidol Decanoate	Haloperidol Decanoate	13	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	13	suppressed
Paliperidone Er	Paliperidone	13	suppressed
Atorvastatin Calcium	Atorvastatin Calcium	11	suppressed
Dayvigo	Lemborexant	11	suppressed
Metformin Hcl Er	Metformin Hcl	11	suppressed
Metoprolol Succinate	Metoprolol Succinate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$217,976.36 · 493 records	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, CAPLYTA, COBENFY, INGREZZA, INVEGA SUSTENNA, INVEGA TRINZA, LYBALVI, NEUROSTAR TMS THERAPY SYSTEM, REXULTI, SPRAVATO, VIVITROL, VRAYLAR	11	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Abilify Maintena play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error